Standard of Care) study for alogliptin (58, 62), the Savor-TIMI-53 study (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes MellitusThrombolysis in Myocardial Infarction 53) for saxagliptin (60, 63), the TECOS study (Trial Evaluating Cardiovascular Outcomes With Sitagliptin) for sitagliptin (59, 64) and the CARMELINA study (Cardiovascular safety and Clinical Outcome with Linagliptin) for linagliptin (61, 65)
These digest slowly and are more likely to reach the specialised L-cells in the gut
However, in a study of weekly dulaglutide, there was a comparable incidence of GI adverse effects in those above and below 65 years of age (117)
Ghoos YF, Maes BD, Geypens BJ, Mys G, Hiele MI, Rutgeerts PJ, et al